BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge - 2What's your #1 tone
- 3Understanding Various Sorts of Financial balances: An Extensive Outline
- 4In blow to Lula, Brazil Congress revives controversial environmental bill
- 5Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- Catholic influencer shares death of 5-year-old son from 'severe' flu
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- Which Startup's Innovation Could Reform Medical care?
- Shrewd Home Gadgets to Save Energy
- From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
- Blue Origin's next space tourism flight will break new ground for people with disabilities
- Ergonomic Office Seats for Work spaces
- Volcanic eruption led to the Black Death, new research suggests
- An Extended time of Self-Reflection: Self-awareness through Journaling
